VEGFA and pulmonary fibrosis: Nintedanib is an inhibitor of platelet-derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor and is a licenced treatment for idiopathic pulmonary fibrosis (IPF) with antifibrotic properties20–22.